Patent SG-11201811074R-A (SG)
Title: Nant cancer vaccine
Inventor: SOON-SHIONG PATRICK
IPC: A61K31/69
Filed: 2017-06-30
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111011101 HIM 01101010111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number 0 (43) International Publication Date .....0\"\" WO 2018/005973 Al 04 January 2018 (04.01.2018) W I PO I PCT — (51) (21) (22) (25) Filing Language: (26) (30) International Patent Classification: NANTCELL, INC. [US/US]; 9920 Jefferson Boulevard, A61K 38/38 (2006.01) A61K 31/69 (2006.01) Culver City, California 90232 (US). A61K 39/395 (2006.01) A61K 39/00 (2006.01) (72) Inventors: SOON-SHIONG, Patrick; 9920 Jefferson A61K 31/4184 (2006.01) Boulevard, Culver City, California 90232 (US). NIAZI, International Application Number: Kayvan; 9920 Jefferson Boulevard, Culver City, Califor- PCT/US2017/040297 nia 90232 (US). RABIZADEH, Shahrooz; 9920 Jefferson Boulevard, Culver City, California 90232 (US). International Filing Date: 30 June 2017 (30.06.2017) (74) Agent: FESSENMAIER, Martin; Umberg Zipser LLP, 1920 Main Street, Suite 750, Irvine, California 92614 (US). English Publication Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, Priority Data: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/357,324 30 June 2016 (30.06.2016) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/371,665 05 August 2016 (05.08.2016) US DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/393,528 12 September 2016 (12.09.2016) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/404,753 05 October 2016 (05.10.2016) US KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 62/463,037 24 February 2017 (24.02.2017) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/473,207 17 March 2017 (17.03.2017) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/474,034 20 March 2017 (20.03.2017) US SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Applicants: NANT HOLDINGS IP, LLC [US/US]; 9920 Jefferson Boulevard, Culver City, California 90232 (US). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) = — Title: NANT : from the escape phase of cancer immunoediting to the elimination and equilibrium phase of cancer immunoediting. (54) CANCER VACCINE r— ed g OPS Mu /AO.. NW: a az • o• `,ara _ that drive a = 3 , '• = = = - - = = = i r „ Killer Ille I IOW fliK) CO a , C¢33 4' .06Ine T ,.0 4? s s i ua Cold Oss.th D, , ,!; ,E; t,, ,,, ,,..ptamcv , .. = = - TI M IN 01 ir) 0 0 --..... 00 Il (57) C:::: ) tumor ei C Figure 2 Cancer is treated using coordinated treatment regimens that uses various compounds and compositions [Continued on next page] WO 2018/005973 Al MIDEDIMOMOIDEIREEMOOVIIMIMOillini0VOIS GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with amended claims (Art. 19(1))